ECSP12012352A - Agente terapéutico de liberación sostenida para la hipertensión y la disfunción renal - Google Patents

Agente terapéutico de liberación sostenida para la hipertensión y la disfunción renal

Info

Publication number
ECSP12012352A
ECSP12012352A ECSP12012352A ECSP12012352A EC SP12012352 A ECSP12012352 A EC SP12012352A EC SP12012352 A ECSP12012352 A EC SP12012352A EC SP12012352 A ECSP12012352 A EC SP12012352A
Authority
EC
Ecuador
Prior art keywords
hypertension
renal dysfunction
therapeutic agent
sustained release
release therapeutic
Prior art date
Application number
Other languages
English (en)
Inventor
Takashi Shirakura
Mizuho Tamura
Yoshimasa Takahashi
Ippei Kuwahara
Original Assignee
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45371556&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP12012352(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd
Publication of ECSP12012352A publication Critical patent/ECSP12012352A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención da a conocer un agente terapéutico o preventivo para la hipertensión o la presión sanguínea alta normal, y para la disfunción renal, que es más eficaz que las drogas existentes.Más específicamente, la presente invención da a conocer una composición farmacéutica de liberación sostenida para el tratamiento o prevención de la hipertensión o la presión sanguínea alta normal, y para la disfunción renal, que comprende, como ingrediente activo, un compuesto de 2-feniltiazol representado por la siguiente fórmula (I)Fórmula química 1 (I)o una sal farmacéuticamente aceptable del mismo.
ECSP12012352 2010-06-25 2012-12-20 Agente terapéutico de liberación sostenida para la hipertensión y la disfunción renal ECSP12012352A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2010145056 2010-06-25

Publications (1)

Publication Number Publication Date
ECSP12012352A true ECSP12012352A (es) 2013-02-28

Family

ID=45371556

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP12012352 ECSP12012352A (es) 2010-06-25 2012-12-20 Agente terapéutico de liberación sostenida para la hipertensión y la disfunción renal

Country Status (25)

Country Link
US (1) US20130109726A1 (es)
EP (1) EP2586442A4 (es)
JP (1) JPWO2011162390A1 (es)
KR (1) KR20130088755A (es)
CN (1) CN102958521A (es)
AR (1) AR082022A1 (es)
AU (1) AU2011270133B2 (es)
BR (1) BR112012032543A2 (es)
CA (1) CA2803163A1 (es)
CL (1) CL2012003661A1 (es)
CO (1) CO6660504A2 (es)
EC (1) ECSP12012352A (es)
MA (1) MA34328B1 (es)
MX (1) MX2012015040A (es)
MY (1) MY160963A (es)
NZ (1) NZ605516A (es)
PE (1) PE20130241A1 (es)
RU (1) RU2013103366A (es)
SG (1) SG186798A1 (es)
TN (1) TN2012000568A1 (es)
TW (1) TW201215389A (es)
UA (1) UA107716C2 (es)
UY (1) UY33468A (es)
WO (1) WO2011162390A1 (es)
ZA (1) ZA201209388B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA112632C2 (uk) 2010-06-16 2016-10-10 Такеда Фармасьютикалз Ю.Ес.Ей., Інк. Дозована форма з модифікованим вивільненням фебуксостату (варіанти)
KR101797936B1 (ko) 2010-09-10 2017-11-15 다케다 파마슈티칼스 유에스에이, 인코포레이티드 테오필린과 페북소스타트의 병용 치료 방법
MX2014008484A (es) * 2012-01-27 2014-10-14 Teijin Pharma Ltd Agente terapeutico para la diabetes mellitus.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992009279A1 (en) 1990-11-30 1992-06-11 Teijin Limited 2-arylthiazole derivative and pharmaceutical composition containing the same
WO2003013543A1 (en) * 2001-08-08 2003-02-20 Genomed, Llc Treatment or prevention of acute renal failure
CA2617248C (en) * 2005-08-03 2015-09-29 Tap Pharmaceutical Products, Inc. Methods for treating hypertension
US9028867B2 (en) * 2005-08-18 2015-05-12 Teijin Pharma Limited Formulation having accurate dose-dividing function
BRPI0718611A2 (pt) * 2006-11-13 2014-02-25 Takeda Pharmaceuticals North America Inc Métodos para preservar a função renal utilizando inibidores da xantina oxidoredutase.
CN101658505A (zh) * 2009-09-29 2010-03-03 北京华禧联合科技发展有限公司 非布索坦的缓释制剂及其制备方法
UA112632C2 (uk) * 2010-06-16 2016-10-10 Такеда Фармасьютикалз Ю.Ес.Ей., Інк. Дозована форма з модифікованим вивільненням фебуксостату (варіанти)

Also Published As

Publication number Publication date
ZA201209388B (en) 2013-08-28
CO6660504A2 (es) 2013-04-30
MY160963A (en) 2017-03-31
US20130109726A1 (en) 2013-05-02
AR082022A1 (es) 2012-11-07
PE20130241A1 (es) 2013-03-04
KR20130088755A (ko) 2013-08-08
CA2803163A1 (en) 2011-12-29
AU2011270133A1 (en) 2013-01-10
EP2586442A4 (en) 2014-01-01
JPWO2011162390A1 (ja) 2013-08-22
AU2011270133B2 (en) 2014-03-20
SG186798A1 (en) 2013-02-28
RU2013103366A (ru) 2014-07-27
BR112012032543A2 (pt) 2016-11-22
MX2012015040A (es) 2013-02-07
CN102958521A (zh) 2013-03-06
NZ605516A (en) 2015-02-27
CL2012003661A1 (es) 2013-04-01
MA34328B1 (fr) 2013-06-01
TN2012000568A1 (en) 2014-04-01
UY33468A (es) 2012-01-31
EP2586442A1 (en) 2013-05-01
TW201215389A (en) 2012-04-16
WO2011162390A1 (ja) 2011-12-29
UA107716C2 (ru) 2015-02-10

Similar Documents

Publication Publication Date Title
PH12018501807A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseas
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
MX2020010151A (es) Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn.
BR112013026257A2 (pt) derivados de glicosídeo e usos dos mesmos para o tratamento de diabetes
SV2011004077A (es) Derivados aminobutiricos sustituidos como inhibidores de neprilisina
MY161001A (en) Tetrahydrocarboline Derivative
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
BR112012029170A2 (pt) fármaco antimalárico que contém ácido 5-aminolevulínico ou um derivado do mesmo como um princípio ativo
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
ECSP13012812A (es) Formulaciones inmunosupresoras
BR112012006010A2 (pt) composto de glicina
CR20140005A (es) Una nueva composición terapéutica que contiene apomorfina como principio activo
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
CO6280474A2 (es) Composicion farmaceutica para el tratamiento de la eyaculacion precoz
UY30847A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
PE20151607A1 (es) Formulaciones de compuestos organicos
ECSP12012352A (es) Agente terapéutico de liberación sostenida para la hipertensión y la disfunción renal
BR112012020377A2 (pt) utilização de um ou mais selecionado do grupo constituído por um composto da fórmula (i), uma mistura racêmica-diastereomérica e um isômero óptico do referido composto, e um sal farmaceuticamente aceitável e uma pródroga do mesmo, método, composição farmacêutica e kit para tratamento de caquexia e embalagem comercial
CO6290762A2 (es) Nuevos derivados quinazolin-2, 4-diona y una composicion farmaceutica para prevenir a tratar la enfermedad neurocerebral
PE20130308A1 (es) Metodos para tratar infecciones bacterianas recurrentes
BR112012024346A2 (pt) agente terapêutico ou agente profilático para a doença de alzheimer
BR112012020415A2 (pt) composição farmacêutica para a prevenção ou tratamento da osteoartrite
AR083780A1 (es) Composicion farmaceutica para tratar infecciones del hcv
ECSP099733A (es) Composición farmacéutica que comprende la combinación del agente antimicrobiano ciprofloxacino y el agente antioxidante ácido ascórbico para el tratamiento de infecciones urinarias
AR110330A1 (es) Uso de derivados de bencimidazol para escape ácido nocturno